SIGNIFICANT ROLE OF AI IN CLINICAL TRIALS: ENHANCING EFFICIENCY, ACCURACY, AND PATIENT OUTCOMES

Naga Manikanta Madduri*, Yash Pal and Sagarika Bandi

Pharm D 6th Year, Parul University, Parul Institute of Pharmacy Vadodara, Gujarat 391760.

*Corresponding Author: Naga Manikanta Madduri

Pharm D 6th Year, Parul University, Parul Institute of Pharmacy Vadodara, Gujarat 391760.

Email ID:

ABSTRACT

Artificial intelligence (AI) is revolutionizing clinical trials by enhancing efficiency, accuracy, and patient outcomes. Through advanced algorithms, AI optimizes trial design, accelerates patient recruitment, and improves data management. AI-driven predictive models enable better selection of trial candidates by analyzing complex data from medical records, genetic profiles, and lifestyle factors. In drug discovery, AI expedites target identification and reduces the time needed for clinical trial phases. Machine learning algorithms can detect patterns in large datasets, improving the accuracy of trial results and minimizing errors. AI tools, such as natural language processing, streamline data collection and analysis, while wearable devices integrated with AI provide real-time patient monitoring, ensuring better adherence and safety oversight. Moreover, AI facilitates adaptive trial designs that adjust in real-time based on patient responses, enhancing personalized treatment strategies. As AI continues to evolve, it holds the potential to significantly transform clinical trials, leading to faster, more accurate, and patient-centered research outcomes.

KEYWORDS: Artificial intelligence, Clinical trials, Clinical data management.

INTRODUCTION

Artificial Intelligence (AI) is playing an increasingly pivotal role in the transformation of clinical trials, offering groundbreaking solutions to improve efficiency, accuracy, and patient outcomes. Clinical trials, which are essential for the development of new treatments and therapies, are often time-consuming, expensive, and logistically challenging. Traditional methods face significant obstacles, such as recruiting eligible participants, managing and analyzing large amounts of data, and ensuring the accuracy of trial outcomes.[1-2] One key area where AI is having an impact is in patient recruitment. By analyzing large datasets from electronic health records (EHRs) and social media, AI can identify eligible participants more quickly and accurately, reducing delays caused by manual screening. Furthermore, AI algorithms can predict patient dropout risks by analyzing behavioral and medical data, ensuring more consistent participant retention. AI also improves trial design and optimization by using machine learning models to simulate various trial scenarios. These models help in identifying the most effective trial protocols and endpoints, increasing the likelihood of success. In addition, AI can analyze vast amounts of real-time data during trials, identifying patterns and trends that may not be apparent to human researchers. This enables adaptive trial designs where protocols can be modified in real-time based on emerging data, thereby increasing trial efficiency.[3] Moreover, AI-powered natural language processing (NLP) assists in mining relevant medical literature, reports, and clinical notes, helping researchers stay updated with the latest findings and reduce redundancy in trial design. AI also plays a crucial role in drug safety by detecting potential adverse effects earlier, using predictive analytics and pattern recognition.[4] In summary, AI is transforming clinical trials by enhancing patient selection, optimizing trial design, enabling real-time data analysis, and improving safety monitoring. These advancements are reducing the time and cost associated with clinical trials while increasing their success rates, ultimately accelerating the availability of new and effective treatments.[5] A clinical trial's potential participants may be uncovered by using AI to comb through mountains of medical information. Researchers at New York's Mount Sinai Medical Centre, for instance, analysed electronic health records (EHRs) and genetic data using topological data analysis (TDA) to classify people with type 2 diabetes into three categories.[7] In recent years, AI has demonstrated its potential to enhance the efficiency, accuracy, and overall quality of clinical trials. By automating routine tasks, improving patient recruitment strategies, and optimizing data

analysis, AI addresses key challenges that have long hindered the trial process. Furthermore, AI-driven tools and models can predict patient responses, identify safety concerns earlier, and facilitate real-time monitoring of trial outcomes.[6] This review article will explore the significant roles AI plays in clinical trials, focusing on how it streamlines operations, and improves patient outcomes. Additionally, the article will highlight the impact of AI in various stages of clinical trials, including patient enrollment, data collection, monitoring, and clinical data management, while also addressing the ethical considerations and limitations that accompany the adoption of this technology.

Role of ai in design of trail
Predicting patient outcomes in clinical trials (CTs) is pivotal for advancing precision medicine and enhancing trial design by reducing statistical variability. AI algorithms can simulate data to improve statistical outcome measures and predict participant outcomes, potentially shortening trial durations by identifying individuals who may progress faster.[8] By analyzing Electronic Medical Records, AI can also forecast the likelihood of participants dropping out. Rather than excluding these participants, particularly in cardiovascular trials, targeted interventions such as additional education have been implemented to extend their involvement. AI-driven tools can help reduce sample sizes and, consequently, the number of participants needed.[9-10] One study highlighted the use of machine learning (ML) models to reduce cancer mortality by 15-25% across multiple CTs. These models, which incorporate environmental and genetic factors, are built from large biological databases correlating predictive biomarkers with survival outcomes, as demonstrated in Non–Small Cell Lung Cancer trials.[11] By tailoring drug selection and adapting investigational drugs to specific cancer profiles, AI can enhance survival rates and transform trial design. AI also supports predicting the probability of trial success. ML algorithms can detect diseases early and improve trial outcomes, including predicting molecular characteristics, drug sensitivity, and toxicity during early research phases. This helps mitigate later-stage trial failures, increasing the likelihood of PhII/PhIII trial success and regulatory approval.[12] By understanding success factors in each phase—such as clinical endpoints and protocol complexity—ML models can inform better trial designs. In oncology, AI is being applied to in-silico trials, using clinical data to simulate cohorts and predict treatment effectiveness, though the lack of high-quality datasets remains a challenge. AI is also reshaping trial design. It improves cohort composition, adherence, and endpoint selection through faster, more accurate hypothesis generation and disease evolution understanding.[13] Virtual control arms using synthetic data could replace placebo groups, reducing ethical concerns and trial costs, though significant investments in datasets and validation are required. Nonetheless, collaborative efforts to standardize data collection and organization are essential

for maximizing AI's potential. Ethical considerations surrounding data misuse remain a critical challenge.[14]

Role of ai in subject recruitment
Recruiting participants for clinical trials (CTs) is a significant challenge, often leading to delays and increased costs. The difficulty arises from several factors, such as intricate trial protocols, limited awareness, fear of participation, and general lack of interest. Additionally, increasingly complex inclusion and exclusion criteria make it harder to find eligible patients who meet the necessary standards, minimizing risks of confounders or misclassifications.[15] However, AI tools are proving beneficial across various therapeutic areas by analyzing demographic, laboratory, imaging, and -omics data to match participants with the stringent criteria required for recruitment. AI could also enhance patient selection through automated trial recommendations, reaching a wider audience via public CT platforms. Moreover, by utilizing extensive datasets, especially in the metabolic field, AI contributes to fairer trial access, as shown in an HIV study.[16] This shows AI's potential in improving awareness and matching participants in clinical trials. The effective use of AI tools in recruitment largely depends on the implementation of standardized language for eligibility criteria to ensure system interoperability.[17] These tools must accurately interpret and process the input data for their intended function. Combining structured data with natural language processing insights from patient reports can enhance eligibility screening. Recent advancements, like a clinicaltrials.gov database that extracted eligibility criteria from over 350,000 trials, show promising results.[18-19] Additionally, AI could streamline investigator ranking based on past performance, accelerating site initiation and improving recruitment efficiency.[20]

Role of ai in conduct of trail
Digital health technologies (DHTs) are increasingly integrated into clinical trials through automated data collection tools and the development of AI-powered digital biomarkers. These innovations enable near real-time monitoring of participants' conditions via wearable devices and sensors, providing investigational sites with immediate insights.[21] This capability enhances participant safety, particularly for those with serious or debilitating conditions, by offering faster access to actionable data. In psychiatric and neurological trials, DHTs have also been used to address the ongoing challenge of ensuring investigational medicinal product (IMP) adherence. Traditional methods, such as tracking when participants open their IMP packages, have shown limitations in accuracy. AI can offer a more reliable alternative, such as video capture devices with AI algorithms to confirm medication intake.[22-23] This approach is considered one of the few effective ways to verify drug adherence remotely, as in-person monitoring by clinical staff is often impractical. AI also shows promise in the analysis and workflow management of

medical images, where it can automate the annotation of key markers and reduce the time experts spend on image classification. However, building a robust, standardized image repository for algorithm training remains a significant challenge.[24]

Role of ai in analysis of data

Identifying treatment effect heterogeneity is a significant challenge for clinical trial (CT) statisticians, as true homogeneous treatment effects are rare. AI tools, trained on cardiovascular datasets, have been employed to analyze CT data and uncover subgroups with varying treatment responses, as well as to identify crucial risk factors and rapid responders in specific populations. These advancements offer the potential for more thorough analysis and valuable insights for drug development. However, achieving regulatory approval remains a hurdle, necessitating full validation of these AI-derived results.[25-26] During the COVID-19 pandemic, many CTs were disrupted due to resource reallocations, travel restrictions, and participant health concerns, leading to missing data and delayed study visits. Machine learning (ML) can be utilized to impute missing data and assess participant conditions when visits fall outside protocol-defined windows. Additionally, AI tools have the potential to automate the extraction of data into statistical analysis software, minimizing manual effort and reducing the risk of human error. Nonetheless, the development and validation of these algorithms remain key challenges.[27]

Role of ai in clinical trial management

Artificial intelligence (AI) has become an integral tool in medical practice, particularly in clinical trials, where it plays a key role in streamlining patient recruitment, cohort composition, and ongoing trial monitoring. By leveraging predictive analytics, AI simplifies the complex process of identifying suitable candidates for trials, automating the screening and assessment of participants based on predefined criteria. This technology also provides trial recommendations, ensuring the selection of appropriate participants. One of AI's major contributions is the automation of data collection and management, from initial candidate screening to the final recording of trial outcomes. This has resulted in significant reductions in both time and cost, while improving data accuracy. AI gathers data from various sources such as electronic health records, medical devices, and wearable technologies, ensuring standardized formats and minimizing inconsistencies. Furthermore, AI systems can detect missing values, incorrect data entries, and flag discrepancies for review, enhancing data quality.[28-29] Machine learning (ML), a subset of AI, has proven particularly valuable in optimizing trial design and predicting outcomes. By utilizing accurate data, researchers can better anticipate trial results and identify high-risk patients for targeted interventions, which improves overall patient outcomes. AI-driven tools also streamline patient recruitment by accelerating the screening process for large cohorts and improving retention through efficient early-stage data management. Additionally, AI enhances data quality throughout the trial, automating not only data collection but also its cleaning and analysis. This reduces the risk of human error and boosts the reliability of trial results. AI's real-time monitoring capabilities allow for the prompt detection of issues, enabling investigators to take timely corrective action, which further strengthens the trial process.[30] Moreover, AI-powered platforms help optimize trial design, reducing the likelihood of trial failure and improving success rates. By automating data analysis, AI cuts down on manual labor and costs while increasing the precision of trial outcomes. AI also facilitates real-time data collection during trials, providing investigators with actionable insights for refining and optimizing trial designs. Machine learning, in particular, excels at integrating digital health technologies like wearables, speech recognition, and computer vision, enabling remote monitoring of patients and capturing real-time biometric data.[31] This allows researchers to track the long-term effects of treatments in real-world settings, reducing the need for traditional study visits. Wearable devices contribute patient-generated data, introducing novel digital biomarkers that enhance the efficiency and patient-centered focus of clinical trials. However, these new biomarkers require FDA approval before widespread use, and their integration with established clinical endpoints demands further exploration. Transparent communication about the risks and benefits of data collection is also critical to addressing privacy and ethical concerns, as these could impact participant recruitment and retention if not properly managed.[32]

Role of ai in improve patient safety in clinical trials

AI is also making strides in improving patient safety during trials. AI significantly enhances patient safety in clinical trials by streamlining data analysis, monitoring, and risk assessment. AI algorithms can analyze vast datasets to identify potential safety issues and adverse effects in real-time, allowing for timely intervention. Machine learning models predict patient responses and optimize trial designs, minimizing exposure to ineffective or harmful treatments. Additionally, AI facilitates patient recruitment by matching individuals with appropriate trials based on their health profiles, ensuring better monitoring and adherence. Overall, AI's ability to process complex data and automate routine tasks improves patient safety and enhances the overall efficiency of clinical trials. By leveraging predictive analytics, AI can detect early warning signs of adverse events or side effects in patients. This allows researchers to intervene promptly, ensuring that patients receive appropriate care and reducing the risk of trial-related complications. AI's predictive capabilities extend to drug safety as well, where it can predict potential toxicities or interactions before a drug is widely used, enhancing the overall safety profile of new therapies.[33-34] A review of various studies reveals a significant lack of standardized benchmarks for assessing AI models in healthcare.

Despite differences in AI performance, most studies have demonstrated a positive impact on patient safety outcomes, suggesting that these outcomes do not necessarily align with AI performance metrics. For instance, one study reported a relatively low accuracy of 0.63 for the Patient Assisting Net-Based Diabetes Insulin Titration (PANDIT) system, which led to unsafe recommendations in 1.4% of cases where AI-generated suggestions diverged from nurse recommendations, resulting in negative safety outcomes.[35] In contrast, another study using natural language processing to analyze patient safety reports showed a positive impact on safety outcomes, even with an accuracy of 0.53. Similarly, computer-aided diagnostic tools approved by the FDA in the 1990s increased diagnostic recall rates but did not enhance safety or patient outcomes. A key finding from this review is that AI algorithms are rarely evaluated against established clinical standards, which can be misleading when determining their true impact on patient care. For example, the QRISK cardiovascular disease risk algorithm was revised in 2008 (QRISK2) and demonstrated improved performance compared to its predecessor. However, QRISK2 was not validated against a clinical gold standard, and years later, in 2016, the Medicines & Healthcare Products Regulatory Agency identified errors in the algorithm that affected risk estimation in a third of general practitioner surgeries in England. While several global Standards Development Organizations are actively working on standardizing AI in sectors like cloud computing and cybersecurity, healthcare has seen little progress toward such efforts. The field of healthcare is highly specialized, with different departments having unique clinical standards. Thus, healthcare requires "vertical standards" tailored to specific areas, such as drug safety, surgery, or emergency care. When standards are not sufficiently tailored, patient safety may be compromised.[36-39]

Advantages and Limitaion of ai in clinical trials[40]

Advantages	Limitations
AI can transform key steps of clinical trial design, from study preparation to execution, leading to improved trial success rates	Requires significant investment in technology and infrastructure
Improve patient recruitment and protocol design, leading to higher chances of trial success	Requires specialized expertise in both clinical research and machine learning
Monitor patients and analyse data, leading to more accurate measurement and interpretation of results	Raises ethical concerns around data privacy and informed consent
Predict clinical outcomes, which is essential for precision medicine and can help eliminate statistical variability of general populations	Lack of empirical data validating the effectiveness of AI-based medications in planned clinical trials is the main obstacle to successful deployment
Allows healthcare professionals to better understand the patterns and needs of their patients through in-depth data analysis	In clinical trials, it must be verified how accurately the established AI algorithms solution works as compared to the clinical standards like sensitivity and specificity of diagnostic tests

CONCLUSION
Artificial intelligence (AI) is revolutionizing clinical trials by significantly enhancing efficiency, accuracy, and patient outcomes. Through the automation of data analysis, predictive modeling, and patient recruitment, AI accelerates trial processes while human errors. Its ability to analyze vast datasets in real-time leads to more precise results and personalized treatment plans. Moreover, AI-driven algorithms improve patient monitoring and adherence, leading to better safety profiles and faster drug development. Ultimately, AI optimizes trial design and execution, fostering innovative healthcare solutions and improving the overall success rates of clinical trials in modern medicine.

REFERENCES
1. C K, KW J, WW T. How artificial intelligence could redefine clinical trials in cardiovascular medicine: lessons learned from oncology. Personalized Med, 2019; 16(2): 87–92. doi: 10.2217/PME-2018-0130
2. Baum ZJ, Yu X, Ayala PY, et al. Artificial intelligence in chemistry: current trends and future directions. J Chem Inf Model, 2021; 61: 3197–3212.
3. Chopra H, Baig AA, Gautam RK, et al.. Application of artificial intelligence in drug discovery. Curr Pharm Des, 2022; 28: 2690–2703.
4. Ashok, M., Madan, R., Joha, A., & Sivarajah, U. Ethical framework for Artificial Intelligence and Digital technologies. International Journal of Information Management, 2022; 62: 102433.
5. Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Molecular diversity, 2021; 25: 1315-1360.
6. M AG. Creating efficiencies in the extraction of data from randomized trials: a prospective evaluation of a machine learning and text mining tool. BMC Med Res Methodol, 2021; 21(1). 10.1186/S12874-021-01354-2.
7. Li L, Cheng WY, Glicksberg BS, et al. Identification of type 2 diabetes subgroups through topological analysis of patient similarity. Sci Transl Med, 2015; 7: 311ra174.
8. Sangari N, Qu Y. A Comparative Study on Machine Learning Algorithms for Predicting Breast Cancer

Prognosis in Improving Clinical Trials. In: Proceedings – 2020 International Conference on Computational Science and Computational Intelligence, CSCI, 2020; 2020: 813–818. doi:10.1109/CSCI51800.2020.00152

9. CS L, AY L. How Artificial Intelligence Can Transform Randomized Controlled Trials. Translational vision science & technology, 2020; 9(2). doi:10.1167/TVST.9.2.9

10. AV S, IF AB, SB T. Machine learning model to predict oncologic outcomes for drugs in randomized clinical trials. Int J Cancer, 2020; 147(9): 2537–49. doi: 10.1002/IJC.33240.

11. KW S, CH SK. Machine-learning and stochastic Tumor Growth Models for Predicting Outcomes in patients with Advanced Non-Small-Cell Lung Cancer. JCO Clin cancer Inf, 2019; 3(3): 1–11. doi: 10.1200/CCI.19.00046.

12. F Z. Artificial intelligence in drug design. Sci China Life Sci, 2018; 61(10): 1191–204. doi: 10.1007/S11427-018-9342-2.

13. F F. Key indicators of phase transition for clinical trials through machine learning. Drug Discovery Today, 2020; 25(2): 414–21. doi: 10.1016/J.DRUDIS.2019.12.014.

14. FK LK, O G, C K, RB H. The case for AI-driven cancer clinical trials - the efficacy arm in silico. Biochim et Biophys acta Reviews cancer, 2021; 1876(1). 10.1016/J.BBCAN.2021.188572.

15. EH W. The role of machine learning in clinical research: transforming the future of evidence generation. Trials, 2021; 22(1). 10.1186/S13063-021-05489-X.

16. LM JVSA, JC BMRPH. Using supervised machine learning classifiers to estimate likelihood of participating in clinical trials of a de-identified version of ResearchMatch. J Clin translational Sci, 2020; 5(1). 10.1017/CTS.2020.535.

17. JD DB. Development and validation of a machine-learning ALS survival model lacking vital capacity (VC-Free) for use in clinical trials during the COVID-19 pandemic. Amyotroph lateral Scler frontotemporal degeneration, 2021; 22(1): 22–32. doi: 10.1080/21678421.2021.1924207.

18. M A, S E, G G, et al. Reduction of recruitment costs in preclinical AD trials: validation of automatic pre-screening algorithm for brain amyloidosis. Statistical methods in medical research, 2020; 29(1): 151–164. doi:10.1177/0962280218823036

19. JT B. Artificial Intelligence Tool for optimizing eligibility screening for clinical trials in a large Community Cancer Center. JCO Clin cancer Inf, 2020; 4(4): 50–9. doi: 10.1200/CCI.19.00079.

20. O MQ, MA C, DM F. Quantifying representativeness in randomized clinical trials using machine learning fairness metrics. JAMIA open, 2021; 4(3). 10.1093/JAMIAOPEN/OOAB077

21. Weissler EH, Naumann T, Andersson T, et al. The role of machine learning in clinical research:

transforming the future of evidence generation. Trials, 2021; 22(1). 10.1186/s13063-021-05489-x.

22. K G, Z S. Assessing the scope and predictors of intentional dose non-adherence in clinical trials. Therapeutic Innov Regul Sci, 2020; 54(6): 1330–8. doi: 10.1007/S43441-020-00155-X.

23. V K, A A, L Z, et al. Accuracy of machine learning-based prediction of medication adherence in clinical research. Psychiatry research, 2020; 294. doi:10.1016/J.PSYCHRES.2020.113558

24. Mayorga-Ruiz I, Jiménez-Pastor A, Fos-Guarinos B, López-González R, García-Castro F, Alberich-Bayarri Á. The role of AI in clinical trials. Artificial Intelligence in Medical Imaging: Opportunities, applications and risks. Published online January, 2019; 29: 231–43. doi: 10.1007/978-3-319-94878-2_16.

25. BA G. Using machine learning to identify Heterogeneous Effects in Randomized clinical trials-moving beyond the forest plot and into the forest. JAMA Netw open, 2019; 2(3). 10.1001/JAMANETWORKOPEN.2019.0004.

26. WR Z IB. Machine learning for clinical trials in the era of COVID-19. Stat Biopharm Res, 2020; 12(4): 506–17. doi: 10.1080/19466315.2020.1797867.

27. N Z PM. Does including machine learning predictions in ALS clinical trial analysis improve statistical power? Ann Clin Transl Neurol, 2020; 7(10): 1756–65. doi: 10.1002/ACN3.51140.

28. Haug C. J., & Drazen, J. M. Artificial intelligence and machine learning in clinical medicine, 2023. New England Journal of Medicine, 2023; 388(13): 1201-1208.

29. Oren O., Gersh, B. J., & Bhatt, D. L. Artificial intelligence in medical imaging: switching from radiographic pathological data to clinically meaningful endpoints. The Lancet Digital Health, 2020; 2(9): e486-e488.

30. Rivera, S. C., Liu, X., Chan, A. W., Denniston, A. K., Calvert, M. J., Ashrafian, H., & Yau, C. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension. The Lancet Digital Health, 2020; 2(10): e549-e560.

31. Secinaro S., Calandra, D., Secinaro, A., Muthurangu, V., & Biancone, P. The role of artificial intelligence in healthcare: a structured literature review. BMC medical informatics and decision making, 2021; 21: 1-23.

32. Zhou, Y., Wang, F., Tang, J., Nussinov, R., & Cheng, F. Artificial intelligence in COVID-19 drug repurposing. The Lancet Digital Health, 2021; 2(12): e667-e676.

33. McKnight SD. Semi-supervised classification of patient safety event reports. J Patient Saf, 2012; 8(2): 60–64. doi: 10.1097/PTS.0b013e31824ab987.

34. Simon ACR, Holleman F, Gude WT, Hoekstra JBL, Peute LW, Jaspers MWM, Peek N. Safety and usability evaluation of a web-based insulin self-titration system for patients with type 2 diabetes

mellitus. Artif Intell Med, 2013; 59(1): 23–31. doi: 10.1016/j.artmed.2013.04.009.

35. Lehman CD, Wellman RD, Buist DSM, Kerlikowske K, Tosteson ANA, Miglioretti DL, Breast Cancer Surveillance Consortium Diagnostic Accuracy of Digital Screening Mammography With and Without Computer-Aided Detection. JAMA Intern Med, 2015; 175(11): 1828–1837. doi: 10.1001/jamainternmed.2015.5231.

36. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, Brindle P. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ, 2008; 28, 336(7659): 1475–1482. doi: 10.1136/bmj.39609.449676.25. http://europepmc.org/abstract/MED/18573856.

37. Iacobucci G. Computer error may have led to incorrect prescribing of statins to thousands of patients. BMJ, 2016; 13, 353: i2742. doi: 10.1136/bmj.i2742.

38. NIST Leadership in AI: A Plan for Federal Engagement in Developing Technical Standards and Related Tools. National Institute of Standards and Technology U.S. Department of Commerce, 2019; 09. https://www.nist.gov/system/files/documents/2019/08/10/ai_standards_fedengagement_plan_9aug2019.pdf.

39. Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, Thrun S. Dermatologist-level classification of skin cancer with deep neural networks. Nature, 2017; 02, 542(7639): 115–118. doi: 10.1038/nature21056.

40. Chopra H, Annu, Shin DK, Munjal K, Priyanka, Dhama K, Emran TB. Revolutionizing clinical trials: the role of AI in accelerating medical breakthroughs. Int J Surg, 2023; 1, 109(12): 4211-4220. doi: 10.1097/JS9.0000000000000705.